Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO), an emerging growth company incorporated in Delaware, filed this Form 8-K on August 22, 2025. The report addresses regulatory compliance issues regarding its listing on the Nasdaq Global Select Market.
Key Financial Metrics
The filing discloses specific equity figures derived from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025:
- Stockholders' Equity: $7,069,000
- Minimum Equity Requirement: $10,000,000 (Nasdaq Listing Rule 5450(b)(1)(A))
- Minimum Bid Price Requirement: $1.00 (Nasdaq Listing Rule 5450(a)(1))
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the stockholders' equity figure.
Material Changes and Compliance Status
The Company is currently out of compliance with two distinct Nasdaq listing standards:
- Stockholders' Equity Deficiency: Received a deficiency letter on August 22, 2025, due to equity falling below the $10.0 million threshold.
- Minimum Bid Price Deficiency: Received a prior deficiency letter on April 4, 2025, for failing to maintain a $1.00 minimum bid price. The Company remains out of compliance as of the filing date.
Outlook, Management Commentary, and Risks
Compliance Deadlines and Options:
- Equity Compliance: The Company has 45 calendar days (until October 6, 2025) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- Bid Price Compliance: The initial 180-day compliance period expires on October 1, 2025. The Company may be eligible for an additional 180-day period if it transfers its securities to The Nasdaq Capital Market and meets specific market value standards.
- Transfer Option: The Company may apply to transfer its securities to The Nasdaq Capital Market for both deficiencies, provided it meets the continued listing requirements for that tier.
Management Action: The Company is continuing to evaluate available options to regain compliance. The deficiency letters have no immediate effect on the listing of the Company's common stock.
Investor Verification Checklist
- Verify the current stock price to assess the likelihood of meeting the $1.00 minimum bid price requirement by October 1, 2025.
- Monitor the Company's announcement of a compliance plan for the stockholders' equity deficiency by October 6, 2025.
- Review the Form 10-Q for the quarter ended June 30, 2025, to analyze the full balance sheet and cash position.
- Watch for any announcements regarding a potential transfer of listing to The Nasdaq Capital Market.